Biogen Corp (BIIB) - Business Payback Period
Biogen Inc. (BIIB) is expanding its biosimilar portfolio to hedge against patent risks. The drug development process is accelerating through the integration of AI into molecular analysis. The company's weighted average P/E clearly confirms these trends, with the current level sitting around 106.70. However, high promotion costs for Alzheimer's therapy are temporarily limiting operating margin growth.
Analytical breakdowns for Biogen Inc.
- stock quotes and analyst forecast:
- market capitalization indicators:
- book capitalization data:
- company liabilities and liquidity data:
- business earnings and investment ratios data:
BIIB - Net Profit|Future Profit Biogen Inc.|BIIB - Price to Earnings Ratio|Market Cap to Projected Earnings Biogen Inc|BIIB - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Inc.|BIIB - Operating profit EBITDA|Net earnings per share for the last four quarters Biogen|BIIB - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months biogen.com|BIIB - Earnings growth in current year|Net earnings per share growth forecast for next year Biogen Inc.
General company analysis:biogen.com - BIIB
Biogen Inc. possesses high resilience to external shocks due to the humanitarian status of its developments in neurodegeneration. The P/E ratio quantifies the market value of this advantage by comparing the current share price to annual net income. This multiple determines the investment payback period and the premium paid for future growth. By analyzing the price-to-earnings trend, an investor can distinguish the issuer's fundamental strength from short-term speculation.
Key competitors
Price to Earnings Ratio NBIX|P/E Multiple RGC|Business Payback Period Axsome|Price to Earnings Ratio ACADIA Pharmaceuticals Inc ACAD|Xenon Corp (XENE) - Market Cap to Earnings|Viking Therapeutics - P/E Multiple|Market Cap to Net Income Ratio supernus.com (SUPN)|CPRX: P/E Multiple|Market Cap to Earnings Denali (DNLI)|Price to Earnings Ratio Harmony Pharma|Price to Earnings Multiple BHVN (Biohaven Corp)|Price to Earnings Ratio AMLX (Amylyx Pharmaceuticals)|TRVI (trevitherapeutics.com) - Company Value to Net Income|P/E Multiple PRAX (Praxis Precision Medicines, Inc.)|Business Payback Period Anavex (AVXL)|CBLL - Price to Earnings Ratio|PRTA (Prothena Corporation) - Price to Earnings Multiple|ALEC: P/E Multiple|Price to Earnings Ratio annexonbio.com|Price to Earnings Ratio OMER|Neurogene Inc (NGNE) - Business Payback Period|P/E Multiple ACIU|Price to Earnings Ratio VYGR (Voyager Corp)|P/E Multiple NMRA (Neumora Therapeutics)|Business Payback Period scilexholding.com (SCLX)|Tevogen Bio - P/E Multiple|Business Payback Period Alpha Cognition ACOG|CGTX: P/E Multiple|IKT (Inhibikase Pharma) - Price to Earnings Ratio|Price to Earnings Ratio Cassava Sciences, Inc.|Price to Earnings Multiple ASRT (Assertio Therapeutics)|P/E Multiple COYA|VTGN - Market Cap to Earnings|Ovid Therapeutics - Price to Earnings Ratio|P/E Multiple Acumen Pharmaceuticals, Inc ABOS|CRVO - Price to Earnings Ratio|Company Value to Net Income ATHE (Alterity Therapeutics)|clene.com (CLNN) - Price to Earnings Ratio|Market Cap to Earnings PepGen (PEPG)|JUNS (Jupiter Neurosciences) - P/E Multiple|Price to Earnings Ratio RLMD|P/E Multiple ANVS|Business Payback Period gracetx.com|Price to Earnings Ratio Firefly Neuroscience AIFF|ANEW Medical (KLTO) - Market Cap to Earnings|NeuroSense Therapeutics, Ltd. - P/E Multiple|Market Cap to Net Income Ratio Reviva Pharmaceuticals, Inc. (RVPH)|MTVA: P/E Multiple|Market Cap to Earnings neuraxis.com (NRXS)|Price to Earnings Ratio Helius Medical Technologies, Inc.|Price to Earnings Multiple PASG (Passage Bio Corp)|Price to Earnings Ratio NEUP (Neuphoria Therapeutics Inc.)|NERV (Minerva) - Company Value to Net Income|P/E Multiple ATHA (Athira Pharma, Inc.)|Business Payback Period addextherapeutics.com (ADXN)|ALZN - Price to Earnings Ratio|CYCN (Cyclerion Therapeutics) - Price to Earnings Multiple|PTIX: P/E Multiple|Price to Earnings Ratio Pasithea Therapeutics Corp.|Price to Earnings Ratio CRGT|avenuetx.com (ATXI) - Business Payback Period|P/E Multiple BCLI|Price to Earnings Ratio CARA (Cara Therapeutics Inc.)|P/E Multiple CHRO (Chromocell Therapeutics Corporation)|Business Payback Period Eliem Therapeutics, Inc. (ELYM)|Intra-Cellular - P/E Multiple|Business Payback Period longboardpharma.com LBPH|MRNS: P/E Multiple|NKGN (NKGen Biotech Inc) - Price to Earnings Ratio|Price to Earnings Ratio NeuroBo|Price to Earnings Multiple SAGE (Sage Therapeutics Inc)|P/E Multiple SNPX|TRVN - Market Cap to Earnings|Vigil Neuroscience, Inc. - Price to Earnings Ratio|P/E Multiple anewmeds.com WENA|CERE - Price to Earnings Ratio
